Normal view MARC view ISBD view

Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. [electronic resource]

By:

Conran, N

Contributor(s):

Producer: 20011205Description: 632-8 p. digitalISSN:

0007-1188

Subject(s):

Online resources:

Available from publisher's website

In: British journal of pharmacology vol. 134

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.

Back to results

1 Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects.
by Bolla, Sambamoorthy
2 Lecithin vesicles for topical delivery of diclofenac.
by Boinpally, Ramesh R
3 Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients.
by Poondru, Srinivasu
4 Iontophoresis of lecithin vesicles of cyclosporin A.
by Boinpally, Ramesh R
5 Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30.
by Poondru, Srinivasu
6 Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
by Ciuleanu, Tudor-Eliade
7 Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.
by Scott, David A
8 A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
by Puzanov, Igor
9 Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
by Macaulay, Valentine M
10 Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
by Jones, Robin L
11 Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
by Oza, Amit
12 A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
by Yu, Helena A
13 A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
by Mateo, Joaquin
14 Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
by Fassnacht, Martin
15 Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
by Lyne, Paul D
16 Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
by Leighl, Natasha B
17 First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
by Yap, Timothy A
18 Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
by Aronov, Alex M